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The embryonic stem cell test (EST) is an ECVAM-validated assay to detect embryotoxicity. The output of
the assay is the effect of test compounds on the differentiation of murine-derived embryonic stem cells
(D3 cells), recorded by visual analysis of contracting cardiomyocyte-like cells. Incorporation of a system
to assess the contractility in an automated manner is proposed, to increase the throughput in the EST
independent of observer bias. The automated system is based on image recording of each well, resulting
in the area (pixels) and frequency of contractility (Hz). Four test compounds were assessed for their
embryotoxic potency in the 96-well version of the EST, with both manual and automated analysis: 6-
Aminonicotinamide, Valproic Acid, Boric Acid, and Penicillin G. There was no statistically signiﬁcant dif-
ference in the outcome of both methods in the fraction of contractility (p < 0.05), resulting in the same
rank-order of Relative Embryotoxic Potency (REP) values: 6-aminonicotinamide (1) > valproic acid
(0.007–0.013) > Boric Acid (0.002–0.005) > Penicillin G (0.00001). The automated image recording of con-
tractile cardiomyocyte-like cells in the EST allows for an unbiased high throughput method to assess the
embryotoxic potency of test compounds, resulting in an outcome comparable to manual analysis.
 2008 Published by Elsevier Ltd.1. Introduction
Throughout the gestational period, embryos are susceptible to
xenobiotics. Adverse reactions to chemicals or pharmaceutical
compounds could result in developmental toxicity. An example is
Thalidomide, a compound that was used extensively among preg-
nant women in the 1950s, though withdrawn from the market
after observations of its teratogenic potency. Therefore, testing
chemical compounds and pharmaceuticals for their embryotoxic
potential is of importance.
Existing in vivo tests, based on maternal or embryonic exposure
of laboratory animals, are time-consuming and expensive. An alter-
native to the in vivo assessment is offered by in vitro assays like the
whole-embryo culture assay (WEC test) and the micromass assay
(MM), although both still rely on embryos (Piersma et al., 1995;
Spielmann et al., 1997; Genschow et al., 2002; Piersma, 2004).
The embryonic stem cell test (EST) however, is an in vitro tool to as-
sess the developmental toxic potency of test compounds in early
development (Spielmann et al., 1997). This method has been vali-
dated by the European Centre for the Validation of Alternativeevier Ltd.
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Vosselaar, Belgium.Methods (ECVAM) (Genschow et al., 2004). Embryonic stem cells
can differentiate into all cell types of the three germ layers: ectoder-
mal, mesodermal, and endodermal. As a result, a culture of differen-
tiated stem cells will consist of a heterogeneous population with
cells from various lineages (reviewed by (Rohwedel et al., 2001).
A controlled differentiation into one of these lineages can be used
to assess interference of test compounds with these processes.
The EST is based on the formation of embryonic bodies (EBs)
when murine-derived embryonic stem cells (D3 cells) are placed
in a ‘hanging drop’ culture. When subsequently seeded in tissue
culture plates, the cardiomyocyte lineage is the predominant dif-
ferentiation route of the cells, resulting in contractile areas in the
EBs. In the EST, inhibition of differentiation of the cells into con-
tractile cardiomyocytes is manually recorded by microscopic anal-
ysis, as an in vitro measurement of developmental toxicity.
Previously, we have made adaptations to the experimental pro-
cedure of the EST to optimise the differentiation potential and en-
sure a higher throughput of the assay (Peters et al., 2007, 2008; De
Smedt et al., 2008). Implementation of a low attachment 96-well
plate with subsequent seeding of the EBs into a tissue culture
coated 96-well plate increased the maximum number of test com-
pounds. Furthermore, the 96-well format greatly reduced the costs
involved since it requires only about 15% of the cell culture
medium and test compounds compared to the ECVAM-validated
24-well EST (range-ﬁnder and two repeat studies).
Table 1
The test compounds that were assessed for their inhibition of differentiation of D3 cells are 6-Aminonicotinamide (positive control), valproic acid, boric acid, and penicillin G
Na+

















A.K. Peters et al. / Toxicology in Vitro 22 (2008) 1948–1956 1949However, the manual assessment of contractility remained the
quantity-limiting step when multiple compounds were tested for
their embryotoxic potential. Visual examination of contractility
by microscopic analysis is labour-intensive, and could result in a
technician-dependent outcome. Furthermore, the observed con-
tractility is noted in a binominal ‘yes/no contractility observed’,
without taking the variability in the contractile frequency or size
of the contractile area of the EB into account.
Recent modiﬁcations to the EST include addition of various end-
points, such as molecular markers or FACS analysis (Bremer et al.,
2001; Seiler et al., 2004; Zur Nieden et al., 2004; Adler et al., 2005,
2008; Honda et al., 2006). These modiﬁcations result in a more
quantitative output than visual examination, but are not suitable
for the desired high-throughput assessment. Accordingly, there is
a desire to develop a method to automate the assessment of con-
tractility, facilitating the evaluation without possible observer bias.
Walmod and colleagues have reported an automated in vitro
screening of teratogens (Walmod et al., 2002). Based on staining
of murine-derived ﬁbroblasts (L929 cells), automated computer-
ized video recording and detection was used to identify possible
teratogens. With their system, 20 compounds were assessed for
the teratogenic potency based on computerized recognition of
changes in cell morphology and cell proliferation (Walmod et al.,
2004). A different approach of automated screening for develop-
mental toxicity is the quantiﬁcation of the contractility of the
embryonic stem cells. Contractility of cardiomyocytes or calcium
ﬂuctuations have been assessed with confocal laser-scanning
microscopy or detection of ﬂuorescence dyes (Sauer et al., 1998;
Satoh et al., 2000; Dolnikov et al., 2006). However, the manner in
which the EBs contract is not taken into account with these meth-
ods, while there can be large differences in both their size and fre-
quency of contraction.
The objective of the present study is to ensure technician-inde-
pendent and unbiased outcome of the EST by automated assess-
ment of the contractility of embryonic stem cells in a 96-well
format. The following test compounds were chosen to be assessed
both manually and automated: 6-Aminonicotinamide (positive
control), Boric acid, Valproic acid, and Penicillin G (Table 1). The
selection of test compounds was based upon available literature
(Smith et al., 1983; Schwetz and Harris, 1993; Spielmann et al.,
2001; Brown, 2002; Genschow et al., 2004) and previously re-
ported outcomes (Peters et al., 2008).
2. Material and methods
2.1. Chemicals
The chemicals used in the studies were obtained from the fol-
lowing companies: DMSO was purchased from Merck (VWR;
Leuven, Belgium). Dulbecco’s Modiﬁed Eagle’s Medium (DMEMsupplemented with L-glutamine, glucose and NaHCO3), L-gluta-
mine, non-essential amino acids (NEAA), and phosphate buffered
saline (PBS) without Ca2+ and Mg2+ were ordered from Gibco
(Carlsbad, CA, USA). Foetal Calf Serum (FCS; stem cell tested) was
ordered from Hyclone (Perbio Science; Erembodegem-Aalst
Belgium), mLIF (ESGRO 106 U) from Chemicon (Millipore;
Brussels, Belgium), and Penicillin/Streptomycin solution (5000 U/
5000 lg) from Cambrex (VWR; Leuven, Belgium). All other chemi-
cals were ordered at Sigma Aldrich (St. Louis, MO, USA) and dis-
solved in DMSO (ﬁnal solvent concentration 0.25%).
2.2. Cell line and cell culture
Murine-derived embryonic stem cells (D3; Mus Musculus) were
kindly provided by ECVAM (Ispra, Italy), by courtesy of S. Bremer.
The D3 cells were cultured in DMEM supplemented with 20% heat
inactivated FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50 lg/ml
streptomycin, 1% NEAA, and 0.1 mM b-mercaptoethanol. For rou-
tine culture, 1000 U/ml mLIF was added directly to the medium
after seeding the cells. The cells were cultured in a humidiﬁed
atmosphere (5% CO2, 37 C), and routinely subcultured.
2.3. Embryonic stem cell test
The EST was performed as described previously (Peters et al.,
2008). In short, D3 cells were seeded in culture medium in round
bottom low attachment 96-well plates (300 cells/well in 50 ll;
NUNC round bottom low attachmentwell plates ref. 145399). Three
days later, 50 ll fresh medium with test compounds was added.
The embryonic bodies (EBs) formed during the ﬁrst ﬁve days of
the experiment, were transferred into ﬂat bottom tissue culture
96-well plates, with addition of fresh medium with test com-
pounds. After all the EBs were transferred, the tissue culture trea-
ted well plate was placed on a digital orbital mini-shaker with
microtitre plate insert to ensure a central position of the EB in
the well (IKA MS3, Staufen, Germany; ± 250 rpm during approxi-
mately 40 sec), and subsequently placed in the incubator (5%
CO2, 37 C). At the tenth day of the experiment, the contractility
of the cells was assessed visually (Zeiss Axiovert 200, 100X), and
recorded as ‘+’ (contractile areas observed) or ‘–‘ (no contractile
areas observed).
2.4. Statistical Analysis of the EST
Statistical analysis of the dose-response curves from the EST
was performed using GraphPad Prism version 4.00. After an initial
range-ﬁnding experiment, the EST was carried out in two indepen-
dent experiments (10 EBs/concentration) and expressed as ‘frac-
tion contractile EBs’, with 100% implying all EBs exposed to the
same concentration of test compound resulted in contractile areas
1950 A.K. Peters et al. / Toxicology in Vitro 22 (2008) 1948–1956in the EBs. The in vitro relative embryotoxic potency (REP) was cal-
culated relative to the EC50 value obtained for the positive control
(6-Aminonicotinamide) of each independent experiment in ‘frac-
tion contractility’ (Eq. (1) ). The EC50 is the concentration where
50% of the maximally observed effect was reached. When no EC50
value could be determined (no inhibition of differentiation), or
when there was no statistically signiﬁcant difference to the ob-
served decrease in cell viability, the REP was given an arbitrary va-
lue of 0.00001.
EC50value ðpositive control 6ANÞ
EC50value ðtest compoundÞ ¼ REP value ðtest compoundÞ
ð1Þ2.5. Automated assessment of contractility
The image analysis system consists of an Axiovert S100 inverted
microscope (Zeiss, Oberkochen, Germany) with Kohler illumina-
tion (condenser NA = 0.55) equipped with a motorized (x,y)-stage
(Märzhauser, Wetzlar, Germany), focus-drive and a Firewire mono-
chrome CCD-camera (Dolphin F-145B, Allied Vision Technologies,
Stadtroda, Germany). The UGR software (Digital Cell Imaging Labs,
Edegem, Belgium) running on a standard PC (Dell Precision Work-
station with Microsoft Windows XP) was used to control both
stage and camera.
The detection of the embryonic body occurred manually by
moving the stage to the centre of the embryonic body, followed
by an auto-focus step, and subsequent time-lapse image recording.
The recordings were taken with brightﬁeld imaging settings, illu-
minated with a halogen lamp over a time-span of 9 s, using a frame
rate of 3.33 frames/second in greyscale (see Fig. 1). The resolution
of the recorded image was 1.05 lm/pixel, i.e. 1 pixel represents ap-
prox. 1.05 lm2. Image analysis was performed using the Beat Assay
Analysis (BEA) software (Digital Cell Imaging Labs, Edegem,
Belgium). The software detects movement in cells by comparing
each time frame to the previous and next frames of the video se-
quence. The area of contractile cells is computed at each time
point. In some cases, false positive contractile cells were detectedFig. 1. Representative example of the automated assessment of the area contractility of D
an unexposed embryonic body (negative control) during 7 s. The images were manua
contracting cardiomyocyte-like cells. Among the contractions, the location of the area
represented in the Figure was used from second 3 until second 6 (with 3.33 frames/secat the end or beginning of the movie (Fig. 1), as conﬁrmed by visual
examination. This was due to border effects, i.e. not having frames
prior or after the particular frame that was being analysed. The
border effects were avoided by discarding the ﬁrst and last frames
of the compiled movie from the analysis.
The following features were computed with the BEA software
for each time point: the contractile area of the EB for each individ-
ual well (in pixels, Fig. 1), and the frequency of the contractions of
the EB (in Hz, Fig. 2).
2.6. Statistical Analysis of the automated assessment of contractility
The image analysis data was presented as contractile area (pix-
els) and frequency of contractility (Hz). Based on the obtained data
for the area of contractility, the automated image analysis was also
presented in ‘fraction contractility’. To convert the data into ‘frac-
tion contractility’, thresholds were set for empty wells and for
wells containing non-contractile EBs. The outcome of a total of
50 empty wells (data computed for the contractile area) was com-
piled, and based upon the computed data, trial and error resulted
in a threshold of 1500 pixels for empty wells. In a similar way,
the threshold for wells containing non-contractile EBs was set at
5,5000 pixels.
After these thresholds were set, the outcome of the automated
image analysis was converted into ‘fraction contractility’. Compar-
ison between the manual and automated data sets (both in ‘frac-
tion contractility’) was performed with an extra sum-of-squares
F-test (p < 0.05; GraphPad Software, San Diego, CA, USA).
2.7. Cell viability
For the cell viability determination, cells were seeded at a den-
sity of 1000 cells/well in a 96-well plate (tissue culture coated) and
exposed to test compounds two hours later. Medium with test
compounds was refreshed three days later, and after a six day incu-
bation period, replaced with a 0.5 mg/ml MTT (3-(4, 5-dimethylthi-
azol-2-yl)-2, 5-diphenyltetrazolium bromide) solution (60 min) as
described previously (Peters et al., 2008). Subsequently, the plates
were spun (1500 g, 5 min) and formazan was extracted from the3 cells in a single well. The images from left to right are taken 1 s apart and represent
lly blurred to enhance the visual image; the darker coloured areas represent the
as well as the size vary. For the ﬁnal analysis of the area of contractility, the data
ond), to compensate for boundary effects at the beginning and end of the movie.
Fig. 2. Representative example of the automated assessment of the frequency of contractility of D3 cells in a single well. The ﬁgure represents 10 wells, all exposed to the
same concentration (6-Aminonicotinamide, 2 lM). The ﬁrst well (1) was empty (conﬁrmed by visual examination), and the last well (number 10) did not contain contractile
bodies. The other wells (2–9) showed contractile areas, though the variability in frequency among the wells is large. For the ﬁnal analysis of the frequency of contractility, the
data represented in the Figure was used from second 3 until second 6 (with 3.33 frames/second), to compensate for boundary effects at the beginning and end of the movie.
A.K. Peters et al. / Toxicology in Vitro 22 (2008) 1948–1956 1951cells with 100 ll DMSO/well (15 min shaking at 200 rpm). The con-
centration of formazan was determined spectrophotometrically at
570 nm. The assay was performed in three independent experi-
ments with exposure to the test compounds in 6-fold.
2.8. Statistical Analysis of the cell viability assay
Statistical analysis of the cell viability assay was performed
using GraphPad Prism version 4.00. In order to determine whether
the observed effects on the differentiation of the stem cells into the
cardiomyocyte-like cells were due to embryotoxicity or cytotoxic-
ity of the test compounds, the dose-response curves of both assays
were compared to one-another with an extra sum-of-squares F-
test (p < 0.05; GraphPad Software, San Diego, CA, USA). When no
difference between the outcome of the cell viability assay and
the differentiation assay could be observed, the REP was given an
arbitrary value of 0.00001(Peters et al., 2007).
3. Results
Previously, the developmental toxic potency of twelve test com-
pounds was assessed in the 96-well EST format. The outcome of
the EST was compared to the outcome of the cell viability assay
in order to differentiate embryotoxicity from cytotoxicity (extra
sum-of-squares F-test,p < 0.05). The concentrations of the com-
pounds used in the current study were based on these previous
ﬁndings, avoiding a cytotoxic range. In Table 2, the EC50 values
from the cell viability assay (when detectable) are presented.Table 2
The inhibition of differentiation of D3 cells into cardiomyocytes after exposure to test com
Compound Manual assessment of contractility
EC50 (lM) REP value§
run 1–run 2 run 1–run 2
6-Aminonicotinamide (6AN) 5.92–3.55 1–1a
Valproic acid 867.3–523.2 0.007–0.007a
Boric acid 1291–1587 0.005–0.002a
Penicillin G nd-nd 0.00001–0.00001*
The data are presented as EC50 of the fraction contractility (%), and relative embryotoxic
* When no EC50 could be determined (no embryotoxicity), or when there was no statist
arbitrary REP value of 0.00001 was given.
a There is no statistically signiﬁcant difference between the manual and automatic m
their embryotoxic potency resulted in the same order for both the manual as well
mide > Valproic acid > Boric acid > Penicillin G (nd: not detectable).3.1. Embryonic stem cell test – manual assessment of contractility
Exposure of the cells to the test compounds 6-Aminonicotina-
mide (maximum concentration 1.5 lM), Boric acid (maximum
concentration 4.8 mM), and Valproic Acid (maximum concentra-
tion 1.7 mM) resulted in a dose-response relationship when the
outcome of the EST was assessed manually (Figs. 3–5A). Exposure
of the cells to the negative control Penicillin G (maximum concen-
tration 3 mM) did not result in a dose-response relationship after
manual assessment of contractility (Fig. 6A), the EBs retained their
contractile capacity. In Table 2, the EC50 values (lM) and corre-
sponding Relative Embryotoxic Potency (REPmanual) values are pre-
sented (left panel). When the compounds are ranked according to
their REPmanual value, the following order was obtained: 6-Amino-
nicotinamide (1) > Valproic Acid (0.007–0.007) > Boric acid (0.005–
0.002) > Penicillin G (0.00001).
3.2. Embryonic stem cell test – automated assessment of contractility
Automated image analysis of the contractile cells is presented
as ‘contractile area’ (Figs. 3–6B) and ‘frequency of contractility
(Figs. 3–6C). The automated computed data of the area and fre-
quency of the contractions resulted in a large variation. Embryonic
bodies that were close to the side of the well did not pose a prob-
lem for the image analysis of the contractile frequency. However,
the contractile area could not be correctly computed, since the
EBs tended to grow upward and sideward, following the well lin-
ing. This effect was taken into account when thresholds were setpounds was assessed manually (on the left) and automated (on the right)
Automated assessment of contractility Cell viability
EC50 (lM) REP value § EC50 (lM)
run 1–run 2 run 1–run 2
5.352–3.5 1–1 19.7 ± 6.0
709.2–268.9 0.008–0.013 1756.3 ± 392
1196–1672 0.0045–0.0021 2226.0 ± 545
nd-nd 0.00001–0.00001* nd
potency (REP) value from two individual experiments.
ically signiﬁcant difference between the EST and the cytotoxicity determination, an
ethod (p < 0.05, extra-sum-of-squares F-test). Ranking the compounds according to
as the automated method (from strong to non-embryotoxic): 6-Aminonicotina-
Fig. 3. (A) Comparison of the automated and manual assessment of contractility for D3 cells exposed to 6-Aminonicotinamide (expressed as ‘fraction contractility’, average of
two independent runs ±range) resulted in a lack of statistically signiﬁcance among both methods. (B) and (C) the corresponding results of the automated image analysis are
presented in frequency (expressed in Hz, two independent runs ± SD) and area of the contractility (expressed in pixels, two independent experiments ± SD), respectively.
Fig. 4. (A) Comparison of the automated and manual assessment of contractility for D3 cells exposed to Boric acid (expressed as ‘fraction contractility’, average of two
independent runs ±range) resulted in a lack of statistically signiﬁcance among both methods. (B) and (C) the corresponding results of the automated image analysis are
presented in frequency (expressed in Hz, two independent runs ± SD) and area of the contractility (expressed in pixels, two independent experiments ± SD), respectively.
1952 A.K. Peters et al. / Toxicology in Vitro 22 (2008) 1948–1956to convert the data into ‘fraction contractility’: <1500 pixels repre-
sents an empty well, 1500 > pixels < 55,000 represents a non-con-
tractile EB, >55,000 pixels represents an EB with contractile area
(s). Applying these thresholds on the image analysis data of the
area of contractility, allowed for conversion of the data into ‘frac-
tion contractility’. Exposure of the cells to 6-Aminonicotinamide,
Boric Acid, and Valproic Acid resulted in a dose-response relation-
ship between the concentration of test compound and the fractionof contractility, as seen in Figs. 3–5A. Exposure to Penicillin G did
not result in a clear relationship, in concordance with the ﬁndings
after manual assessment (Fig. 6A). The EC50 values (lM) and corre-
sponding REPautomated values are presented in Table 2 (right panel).
Ranking the compounds according to their REPautomated values re-
sulted in the following outcome: 6-Aminonicotinamide (1) > Val-
proic Acid (0.008–0.013) > Boric acid (0.005–0.002) > Penicillin G
(0.00001).
Fig. 5. (A) Comparison of the automated and manual assessment of contractility for D3 cells exposed to Valproic acid (expressed as ‘fraction contractility’, average of two
independent runs ±range) resulted in a lack of statistically signiﬁcance among both methods. (B) and (C) the corresponding results of the automated image analysis are
presented in frequency (expressed in Hz, two independent runs ±SD) and area of the contractility (expressed in pixels, two independent experiments ± SD), respectively.
Fig. 6. (A) Comparison of the automated and manual assessment of contractility for D3 cells exposed to Penicillin G (expressed as ‘fraction contractility’, average of two
independent runs ± range) resulted in statistically signiﬁcant different graphs. Both outcomes did not result in a dose-dependent relationship, with no statistically
signiﬁcantly difference between the different concentrations. (B) and (C) the corresponding results of the automated image analysis are presented in frequency (expressed in
Hz, two independent runs ±SD) and area of the contractility (expressed in pixels, two independent experiments ± SD), respectively.
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contractility
When the outcome of the manual and automated method of
assessment (in ‘fraction contractility’) were compared with an ex-
tra sum-of-squares F-test (p < 0.05; GraphPad Software, San Diego,
CA, USA), no statistically signiﬁcant difference was observed be-tween the data sets. After exposure to 6-Aminonicotinamide, the
EC50 values of both ‘fraction contractility’ (based on the area of
contractility with ﬁxed thresholds for empty wells and non-con-
tractile cells, Table 2), contractile area, and frequency (Table 3)
are in the same order of magnitude: 5.35–3.5 lM, 6.53–4.5 lM,
and 6.75–4.32 lM, respectively. The contractile areas reduce with
increasing concentration of test compound (Fig. 3C), combined
Table 3
The inhibition of differentiation of D3 cells into cardiomyocytes after exposure to test
compounds was assessed with an automated method, and the area (on the left) and
frequency of the contractility (on the right) computed
Compound Contractile area Frequency of contractility
EC50 (lM) EC50 (lM)
6-Aminonicotinamide (6AN) 6.53–4.50 6.75–4.32
Valproic acid nd-665 nd-1278
Boric acid 1464–1749 1002–1718
Penicillin G nd-2320 nd-nd
The data are presented as EC50 (lM) of two independent experiments (nd: not
detectable).
1954 A.K. Peters et al. / Toxicology in Vitro 22 (2008) 1948–1956with a less frequent contraction (Fig. 3B). However, the observed
variability in both the area (Fig. 3C) and frequency of contractility
(Fig. 3B) between the two individual runs are large.
After exposure to Boric acid, the computed contractile area and
frequency (Fig. 4B,C) resulted in a similar variability between the
two independent runs. However, as observed after exposure to 6-
Aminonicotinamide, the obtained EC50 values were comparable
with the data converted to ‘fraction contractility’ (Tables 2 and
3). The decrease in contractile area is concordant with a decreased
frequency (Fig. 4B and C).
Exposure to Valproic acid did not result in a dose-response rela-
tionship for the area and frequency of contractility in one of the
two runs (Fig. 5B and C). The data is difﬁcult to interpret due to
large variability. The obtained EC50 value for the frequency of con-
traction is almost double compared to the EC50 value for the con-
tractile area: 1275 and 665 lM, respectively.
Exposure of the cells to the non-embryotoxic compound Peni-
cillin G did not result in a dose-response relationship when the
data was converted to ‘fraction contractility’, neither for the man-
ual nor for the automated assessment (Fig. 6A). The frequency of
contraction did not decrease with increasing dose (Fig. 6B), while
there does appear to be an inclination for reduction of the contrac-
tile area (Fig. 6C)(not statistically signiﬁcant).
4. Discussion and conclusion
The embryonic stem cell test (EST) is proposed as a tool to de-
tect embryotoxicity early in the development of chemical com-
pounds and pharmaceutical candidates. Developmental toxicity
assessment without the use of laboratory animals is a necessary
amendment to the screening procedure.
However, the current experimental procedure of the EST with
an outcome based on visual assessment of the contractility is
time-consuming. Previously, the throughput of the EST was in-
creased by utilisation of a low attachment 96-well plate that al-
lows for the formation of embryonic bodies (EBs) (Peters et al.,
2008). This resulted in a cost saving by a decreased amount of test
compound and medium required for the assay to approximately
15% that of the ECVAM-validated EST.
In order to improve upon the time-consuming manual assess-
ment of contractility, a method is proposed to automate the assay.
Methods to quantify the contractility of cardiomyocytes can in-
volve singular cells or micro-electrode assays (Reppel et al.,
2004; Garcia-Webb et al., 2007). Higher throughput is offered by
spiked cell cultures in which for instance calcium ﬂuctuations
can be measured, with or without incorporation of ﬂuorescent
markers (Sauer et al., 1998; Dolnikov et al., 2006). However, these
methods are not suitable as a screening tool for high throughput
analysis. The same applies for quantiﬁcation of mRNA expression
or FACS analysis as a tool to detect and quantify the embryotoxic
potential of test compounds (Bigot et al., 1999) reviewed by
(Buesen et al., 2004). Furthermore, the functional capacity of the
cells to contract is not taken into account with these methods.In the current study, automated video recording was assessed
as a tool to quantify the outcome of the EST in the 96-well format,
ensuring an even higher throughput of the assay. The automated
image analysis compiled data regarding the area and frequency
of contractility of a given EB over a designated time-period for each
well. However, while there does seem to be a cyclic contraction in
each singular EB, the observed variability between EBs exposed to
the same concentration of test compound was large (Fig. 2). Fur-
thermore, the area of contraction varied at each time-point, both
in localisation and size (Fig. 1).
Similar observations were previously made by Dolnikov and
colleagues, who reported on the irregular 3D structure of the EBs.
The fact that the contractile cells do not shorten along a single axis
of contraction made them conclude that their image recording is
not linearly indicative for the force of contraction (Dolnikov
et al., 2006). As presented in Fig. 2, a tendency to cyclic contraction
was observed, as computed by the BEA software. The current
in vitro system does not distinguish between differences in dia-
stolic and systolic function, and can therefore not compute a true
rhythmic pulse, opposite to adult cardiomyocytes. Figs. 3–6B and
C are indicative that the computed data concerning the area and
frequency of contractility are difﬁcult to interpret.
However, the observed relationship might be a manner in which
false-negative outcomes in the EST can be excluded. Compounds
that do not appear to inﬂuence the cardiomyocyte differentiation
and are negative when the data are compiled as ‘fraction contractil-
ity’, might still affect the area and frequency contractility of the
cardiomyocytes. Nevertheless, the observed variability among test
runswill remain a difﬁcult factor when reviewing these kind of data.
In the adult heart, cardiomyocytes increase their contraction
force under the inﬂuence of stress factors, to increase the cardiac
output (hypertrophy). Dolnikov and colleagues reported a negative
force-frequency relation in the differentiated embryonic cardio-
myocytes. In other words, a reduction in the amplitude of the con-
traction is expected in the EST. As seen in Figs. 3–6B, there is an
inclination that the decreased fraction contractility was accompa-
nied by a decreased frequency of contraction.
With the low-attachment 96-well plates, occasional attachment
of the cells to the plastic was observed, eliminating those EBs from
further use in the assay. Consequently, this resulted in empty wells
when the EBs were transferred to a tissue-culture treated 96-well
plate on the ﬁfth day of the experiment. Besides the occasional at-
tached cells, EBs could also have been inadvertently left behind in
the original well plate when they were transferred to a second well
plate. When the data of the contractile area was depicted as ‘frac-
tion contractility’, there was a need to include a threshold for these
empty wells (<1500 pixels). In the current setup, the study was con-
sidered acceptable when a minimum of eight EBs was present for
each concentration of the test compounds (Peters et al., 2008). By
now, there are alternatives to the low attachment plates used in
the current studies, that have a similar or even better capacity to al-
low EB formation without attachment of the cells to the wells:
Corning (ref 7007) 96-well ultra low attachment plates (round bot-
tom), and Cellseed Hydrocell 96-well plates (round bottom).
After the threshold was set to distinguish contractile from non-
contractile EBs for the automated image analysis, both manual and
automated methods were presented as ‘fraction contractile EBs’.
The automated image analysis of the contractility proved compara-
ble to the manual assessment, with no statistically signiﬁcant dif-
ference observed (p < 0.05).
When the data presented in Table 2 were compared to previ-
ously reported outcomes, the EC50 values for 6-Aminonicotinamide
and Valproic Acid in the current study are slightly higher than the
range previously reported: 3.5–5.92 lM (lowest and highest ob-
served value of both manual and automated assessment in the cur-
rent study) compared to 2.33±1.18 lM for 6-Aminonicotinamide,
A.K. Peters et al. / Toxicology in Vitro 22 (2008) 1948–1956 1955and 268.9–867.3 lM compared to 270.5 ± 121.4 lM for Valproic
acid (Peters et al., 2008). Boric acid resulted in a lower EC50 value
compared to previous experiments: 1196–1672 lM compared to
1754 ± 53.67 lM (Peters et al., 2008). The observed differences
are considered due to inter-experimental diversity. After exposure
of the cells to Penicillin G, both in the current study with different
methods of assessment as well as in the previous reported data, no
EC50 value could be computed for the negative control Penicillin G.
Ranking the compounds according to their REP values was not
inﬂuenced by these slightly different EC50 values. The rank-order
resulted in the same hierarchy; 6-Aminonicotinamide (1) > Val-
proic Acid (range from 0.007–0.013 in the current study, compared
to 0.011 ± 0.003 as previously reported) > Boric acid (range from
0.002–0.005 in the current study, compared to 0.0014 ± 0.001 as
previously reported) > Penicillin G (0.00001).
In both the ECVAM-validation study as well as additional liter-
ature, the test compounds are presented in three categories of
developmentally toxic potency, being non, moderate and strong
embryotoxic (Smith et al., 1983; Schwetz and Harris, 1993;
Spielmann et al., 2001; Brown, 2002; Genschow et al., 2002,
2004). In the current study, the outcome is presented in a contin-
uous table, with test compounds ranked by their embryotoxic po-
tential, expressed as relative embryotoxic potential (REP; Table 2).
Since the REP values are expressed relative to the outcome of the
positive control 6-Aminonicotinamide of that individual experi-
ment, changes in cell growth among experiments e.g. are taken
into account. However, no unambiguous threshold can be set for
developmental toxicity based on these REP values. Clear non-
embryotoxic compounds such as penicillin G (Fig. 6) are identiﬁed,
but the applicability domain of the EST is not transparent. Receptor
mediated pharmaceuticals with known in vivo activity appear to be
mis-classiﬁed (Paquette et al., 2008). The applicability domain of
the EST should be further investigated since the use of the EST as
an in vitro screening tool, in either 24- or 96-well format, depends
on its reliability to identify developmental toxic test compounds.
Automated image analysis allows for a less time-consuming
hands-on practical approach. The outcome is an objective mea-
surement of the effect of test compounds on the differentiation
of embryonic stem cells, and can be stored for later analysis. Possi-
ble observer bias, as might occur with visual analysis of the con-
tractility, is avoided by the automation.
In order to establish a predictive relationship between the area
and frequency of contractility and to evaluate possible false-nega-
tive responses, more data needs to be generated and analysed with
the automated image analysis method and BEA software. For fu-
ture research, the systemmight be complemented with ﬂuorescent
dyes to assess the inﬂuence of test compounds on the intracellular
calcium concentrations (Viatchenko-Karpinski et al., 1999; Kapur
et al., 2006). As suggested by Schmidt (Schmidt et al., 2001), the
incorporation of markers to assess multiple cell types within the
heterogeneous population of differentiated embryonic stem cells
allows for a more complete picture of the effects of test com-
pounds. Furthermore, staining of the cells with subsequent auto-
mated analysis could offer additional possibilities for assessment
of a variety of markers such as cytotoxicity, morphology, or cell cy-
cle (Walmod et al., 2002). Additionally, the auto-focus step will be
accompanied by automated localisation of the embryonic body in
future experiments. This can occur by applying a density threshold,
since the centre of the EB contains the most dense cell population
in the well plate.Conﬂict of interest statement
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